Page last updated: 2024-09-05

senicapoc and Inflammation

senicapoc has been researched along with Inflammation in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Duan, B; Goldberg, ID; Hao, YJ; Jiang, K; Jung, D; Li, JS; McCormack, S; Narayan, P; Paka, L; Shi, J; Smith, DE; Yamin, M; Zhou, P	1

Other Studies

1 other study(ies) available for senicapoc and Inflammation

Article	Year
Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease. World journal of gastroenterology, 2017, Jun-21, Volume: 23, Issue:23 Topics: Acetamides; Animals; Apoptosis; Biomarkers, Tumor; Diet, High-Fat; Fibrosis; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Inflammation; Intermediate-Conductance Calcium-Activated Potassium Channels; Liver Cirrhosis; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Palmitic Acid; Rats; Rats, Wistar; Thioacetamide; Trityl Compounds; Up-Regulation	2017

Article

Year

Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease.

World journal of gastroenterology, 2017, Jun-21, Volume: 23, Issue:23

Topics: Acetamides; Animals; Apoptosis; Biomarkers, Tumor; Diet, High-Fat; Fibrosis; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Inflammation; Intermediate-Conductance Calcium-Activated Potassium Channels; Liver Cirrhosis; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Palmitic Acid; Rats; Rats, Wistar; Thioacetamide; Trityl Compounds; Up-Regulation

2017